Professor Helen E Bryant
Clinical Medicine, School of Medicine and Population Health
Professor of Cancer Therapeutics
Head of The DNA replication and repair group
Full contact details
Clinical Medicine, School of Medicine and Population Health
GU11, G Floor
The Medical School
Beech Hill Road
91探花
S10 2RX
- Profile
-
For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk
Current PhD Opportunities
-
- Qualifications
-
1991 - 1995 BSc Medical Biochemistry University of Glasgow
1996 - 1999 PhD MRC Virology Unit, Glasgow
2000 - 2003 Post-doctoral Researcher Ludwig Institute of Cancer Research, St Mary麓s Hospital, London.
2003 - 2007 Post-doctoral Researcher YCR Institute for Cancer Studies, University of 91探花.
2007 - 2012 RCUK Academic Fellow YCR Institute for Cancer Studies, University of 91探花.
2012 - 2013 Lecturer Department of Oncology, University of 91探花.
2013 - present Senior Lecturer Department of Oncology and Metabolism, University of 91探花
- Research interests
-
Dr Bryant has worked in the area of genome biology for 20 years. Her lab employs chemists, biologists and clinicians in order to promote a multi-disciplinary approach to translational research.
By understanding the control of the fidelity of DNA replication in normal cells we aim to understand why defects in the proteins involved are associated with cancer. Her aim is to pinpoint differences between dividing tumour cells and dividing normal cells and determine which are important in cancer development. This has enabled the group to develop drugs which can specifically kill the tumour cells rather than just all dividing cells (personalized therapy).
A separate side to Dr Bryant鈥檚 work is the development of novel transition metal-containing photodynamic therapy agents that bind to DNA and induce damage only upon irradiation with specific wavelengths of light. This is a collaboration with Prof. Julia Weinstein in the Department of Chemistry (TUOS).
To this end there are 4 board themes that overlap in the lab.
- Understanding of the cellular pathways activated when DNA replication is perturbed.
- Improving and understanding radiotherapy response
- Identification of the changes in expression of these genes and phenotypic consequences in cancer
- Exploitation of these changes in hypothesis-driven drug development.
- Chemical development of novel therapeutic agents (focus on PDT agents)
Current projects examine these themes in Bladder, Breast, NSCLC, HNSCC and Neuroblastoma.
- Publications
-
Journal articles
- . J Med Chem.
- . Frontiers in Bioengineering and Biotechnology, 11.
- . ESMO Open, 8(1), 101664-101664.
- . Cancer Research, 83(7_Supplement), 3542-3542.
- . Cancers, 13(24).
- . Frontiers in Molecular Biosciences, 8(11).
- . ACS Biomater Sci Eng.
- . Nature Communications, 11(1).
- . Current Protocols in Stem Cell Biology, 54(1).
- . EBioMedicine, 59.
- . Frontiers in Molecular Biosciences, 7.
- . Oncotarget, 11(23), 2141-2159.
- . Oncotarget, 11(13), 1109-1130.
- . Cancers, 11(9).
- . PLoS ONE, 14(7).
- . Oncogenesis, 8(5).
- . Dalton Transactions.
- . Molecular Pharmaceutics, 16(3), 1132-1139.
- . Inorganic Chemistry.
- . Coordination Chemistry Reviews.
- . RSC Advances, 8(18), 9670-9676.
- . DNA Repair, 61, 25-36.
- . DNA Repair, 52, 81-91.
- . European Urology, 71(3), 417-425.
- . Chemistry - A European Journal, 23(2), 234-238.
- . Chemistry - A European Journal, 23(2), 234-234.
- . Pathology.
- . Molecules, 21(10).
- . Oncotarget.
- . European Urology, 69(6), 996-997.
- . Inorganic Chemistry, 55(11), 5623-5633.
- . Scientific Reports, 6.
- . Carcinogenesis, 37(1), 63-71.
- . Photodiagnosis and Photodynamic Therapy, 12(3), 338-339.
- . European Urology Supplements, 14(2), e426-e426b.
- . Journal of Pediatric Hematology/Oncology, 37(4), 245-251.
- . Cancer Epidemiology Biomarkers & Prevention, 24(1), 268-275.
- . Oncotarget, 5(18), 7984-7985.
- . Oncotarget, 5(15), 6375-6386.
- . Clin Cancer Res, 20(7), 1990-2000.
- . Breast Cancer Research(5), R92.
- . Oncogene, 32(46), 5338-5346.
- . Journal of Biological Chemistry, 287(41), 34494-34494.
- . Cell Cycle, 11(5), 990-997.
- . Cancer Research, 72(2 Supplement), A10-A10.
- . Methods Mol Biol, 920, 315-321.
- . Br J Cancer, 104(7), 1098-1105.
- . Genes Chromosomes Cancer, 50(1), 34-42.
- . DNA Repair (Amst), 9(9), 964-975.
- . Cancer Res, 70(13), 5389-5398.
- . J BIOL CHEM, 285(11), 8054-8060.
- . DNA Repair (Amst), 8(12), 1424-1433.
- . Cancer Res, 69(21), 8472-8481.
- . Nucleic Acids Res, 37(19), 6400-6413.
- . EMBO J, 28(17), 2601-2615.
- . Nucleic Acids Res, 37(15), 5105-5113.
- A function for PARP at stalled replication forks. MUTAGENESIS, 22(6), 431-431.
- . Nature, 447(7142), 346-346.
- . Mutat Res, 599(1-2), 116-123.
- . Nucleic Acids Res, 34(6), 1685-1691.
- . Cell Cycle, 4(9), 1176-1178.
- . Mol Cell Biol, 25(16), 7158-7169.
- . Nature, 434(7035), 913-917.
- . J Virol, 78(24), 13460-13469.
- . Biochem Soc Trans, 32(Pt 6), 959-961.
- . J Virol, 76(20), 10290-10298.
- . J Virol, 75(9), 4376-4385.
- . J Virol, 74(23), 11322-11328.
- . J Biol Chem, 274(41), 28991-28998.
- . Nature Communications, 15(1).
- . Cell Death & Disease, 15(2).
- . JBIC Journal of Biological Inorganic Chemistry.
- . Pharmaceutics, 13(3), 367-367.
Chapters
- , Methods in Cell Biology (pp. 69-87). Elsevier
- , Cancer Drug Discovery and Development (pp. 315-344). Springer International Publishing
Conference proceedings papers
- Production of porous polycaprolactone polyHIPEs as substrates for in vitro 3D breast cancer cell culture. TISSUE ENGINEERING PART A, Vol. 29(13-14)
- Production of porous polycaprolactone polyHIPEs as substrates for in vitro 3D breast cancer cell culture. TISSUE ENGINEERING PART A, Vol. 29(13-14)
- Investigation of Aurora Kinase A as a Potential Biomarker of Radiation in Non-Small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, Vol. 16(10) (pp S1163-S1164)
- Artificial Neural Network-Based Tumour Recurrence Prediction in Non-Small Cell Lung Cancer Patients Following Radical Radiotherapy. JOURNAL OF THORACIC ONCOLOGY, Vol. 16(10) (pp S958-S958)
- Investigating the effect of replication stress and other phenotypic factors as determinants of sensitivity to single agent ATR inhibitor, VE-821 in ovarian cancer cell lines. EUROPEAN JOURNAL OF CANCER, Vol. 103 (pp E32-E32)
- UPR Activation via glucose deprivation and depletion of GRP78 protein (using siRNA) do not alter radiosensitivity in the human breast cancer cell line MCF7. EUROPEAN JOURNAL OF CANCER, Vol. 49 (pp S425-S425)
- . The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response, Vol. 129 (pp 17-17)
Preprints
- Research group
-
- Polly Gravells - Postdoctoral Research (Biologist)
- David King - Clinical Lecturer
- Saskia Roetschke - Clinical Research Fellow
- Marta Martinez - Postdoctoral Researcher (Chemist)
- Emma Grant - Postgraduate Student
- Callum Jones - Postgraduate Student
- Chris Legge - Postgraduate Student
- Thomas Jones - Postgraduate Student
- Fatma Bucklain - Postgraduate Student
- Hannah Gagg - Technician
- Teaching interests
-
2012 - Postgraduate certificate in Learning and Teaching
Fellow of the Higher Education Academy
MSc - Translational Oncology
MSc - Molecular Medicine
Undergraduate - Genome Stability & Genetic Change module